Back to Search Start Over

Antibody Deficiency in Patients with Biallelic KARS1 Mutations.

Authors :
Saettini F
Guerra F
Fazio G
Bugarin C
McMillan HJ
Ohtake A
Ardissone A
Itoh M
Giglio S
Cappuccio G
Giardino G
Romano R
Quadri M
Gasperini S
Moratto D
Chiarini M
Akira I
Fukuhara Y
Hayakawa I
Okazaki Y
Mauri M
Piazza R
Cazzaniga G
Biondi A
Source :
Journal of clinical immunology [J Clin Immunol] 2023 Nov; Vol. 43 (8), pp. 2115-2125. Date of Electronic Publication: 2023 Sep 28.
Publication Year :
2023

Abstract

Biallelic KARS1 mutations cause KARS-related diseases, a rare syndromic condition encompassing central and peripheral nervous system impairment, heart and liver disease, and deafness. KARS1 encodes the t-RNA synthase of lysine, an aminoacyl-tRNA synthetase, involved in different physiological mechanisms (such as angiogenesis, post-translational modifications, translation initiation, autophagy and mitochondrial function). Although patients with immune-hematological abnormalities have been individually described, results have not been collectively discussed and functional studies investigating how KARS1 mutations affect B cells have not been performed. Here, we describe one patient with severe developmental delay, sensoneurinal deafness, acute disseminated encephalomyelitis, hypogammaglobulinemia and recurrent infections. Pathogenic biallelic KARS1 variants (Phe291Val/ Pro499Leu) were associated with impaired B cell metabolism (decreased mitochondrial numbers and activity). All published cases of KARS-related diseases were identified. The corresponding authors and researchers involved in the diagnosis of inborn errors of immunity or genetic syndromes were contacted to obtain up-to-date clinical and immunological information. Seventeen patients with KARS-related diseases were identified. Recurrent/severe infections (9/17) and B cell abnormalities (either B cell lymphopenia [3/9], hypogammaglobulinemia [either IgG, IgA or IgM; 6/15] or impaired vaccine responses [4/7]) were frequently reported. Immunoglobulin replacement therapy was given in five patients. Full immunological assessment is warranted in these patients, who may require detailed investigation and specific supportive treatment.<br /> (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Details

Language :
English
ISSN :
1573-2592
Volume :
43
Issue :
8
Database :
MEDLINE
Journal :
Journal of clinical immunology
Publication Type :
Academic Journal
Accession number :
37770806
Full Text :
https://doi.org/10.1007/s10875-023-01584-7